Novant Health institutes for heart, vascular and cancer open new state-of-the-art facility

CHARLOTTE, N.C., Oct. 13, 2020 /PRNewswire/ — Novant Health today announced its seven-story cardiovascular and cancer outpatient facility in the greater Charlotte market is complete. Officially named the Novant Health Claudia W. and John M. Belk Heart & Vascular Institute and Agnes B. and Edward I. Weisiger Cancer Institute, the $165.9 million, 260,000-square-foot investment consolidates all outpatient cardiac and cancer specialists, treatment services and support programs in one location. The building welcomed patients Monday, Oct. 12.

Aerial stills and video of facility

B-roll of facility

“Novant Health is proud to open the doors of this premier facility offering leading-edge treatments, groundbreaking clinical research and personalized, whole-person care for patients with cardiovascular conditions and cancer,” said Eric Eskioglu, MD, executive vice president and chief medical officer for Novant Health. “This is a historic moment for our entire Carolina community to celebrate.”

The medical journey for cardiac and cancer issues is often

Read More

Quanterix Receives National Institutes of Health RADx Contract to Advance Antigen Test for SARS-CoV-2 (COVID-19)

$18.2 million in Phase 2 funding will support the development and scale-up of COVID-19 antigen test based on Simoa® technology

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has entered into a Phase 2 contract with the National Institutes of Health (NIH) through its Rapid Acceleration of Diagnostics (RADx℠) initiative. The contract, which has a total award value of $18.2 million, will accelerate the continued development, scale-up and deployment of a novel SARS-CoV-2 antigen test based on Quanterix’ ultra-sensitive Simoa technology. Preliminary results indicate that the test has the potential to enable detection from a variety of sample types including self-collected capillary blood, saliva and nasal swabs.

“The need for accurate and reliable testing in response to the global COVID-19 pandemic continues, and we are honored to have been selected by the NIH to progress to Phase

Read More

National Institutes of Health Commissions PhysIQ to Develop COVID-19 Digital Biomarker

CHICAGO–(BUSINESS WIRE)–The National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), have awarded physIQ a contract to develop an AI-based COVID-19 Decompensation Index (CDI) Digital Biomarker to address the rapid decline of high-risk COVID-19 patients. Today, high-risk COVID-19 patients and their providers are finding out too late that in the disease continuum they are getting sicker and need urgent care. The new early warning system under development could allow providers to intervene sooner when a COVID-19 patient is clinically surveilled from home and begins to worsen. Rather than relying on point measurements, such as temperature and SpO2, that are known to be lagging or insensitive indicators of COVID-19 decompensation, continuous multi-parameter vital signs will be used to establish a targeted biomarker for COVID-19.

“Despite the technological advances and attention paid to COVID-19, the healthcare community is

Read More